Medicine Matters diabetes

The latest update from the NHS Diabetes Prevention Programme shows that more people than expected are engaging with the scheme.

Researchers from the DiRECT trial have reported large positive effects on liver fat and insulin secretion among people who achieved type 2 diabetes remission in response to a very-low-calorie diet.

An analysis of electronic health records reveals changes in prescribing patterns for type 2 diabetes treatments in the UK over the past decade.

A small study shows high complication rates in young people with type 2 diabetes.

Women with gestational diabetes who gain weight late in pregnancy have an increased risk for adverse birth outcomes, study results presented at the 2018 Diabetes UK Professional Conference in London suggest.

Analysis of data from the EMPA-REG OUTCOME trial suggests that empagliflozin reduces the risk for cardiovascular mortality in patients with type 2 diabetes irrespective of baseline glycated hemoglobin levels or glycemic response.

Kidney function predicts patients’ response to SGLT2 inhibitors even in patients with normal estimated glomerular filtration rate, show real-world data.

Study results presented at the 2018 Diabetes UK Professional Conference in London confirm that people who are diagnosed with type 2 diabetes at a younger age have an increased mortality risk.

A post-hoc analysis of the LEADER trial indicates that liraglutide treatment may reduce the risk for severe hypoglycemia among patients with type 2 diabetes.

An initiative involving “virtual ward” meetings between diabetes specialist nurses, community nurses, and consultants has led to improvements in glycemic control and a reduction in nurse visits among older diabetes patients in North East Essex, study results suggest.

Results of an observational study suggest that doing exercise around the time of type 1 diabetes diagnosis could extend the “honeymoon” period of low insulin requirement.